Congressional Research Service Reports - 206 Matching Results

Search Results

prev Results: 151 - 200 next
Drunk Driving and the National Driver Register
At the 0.08 BAC level of alcohol, braking, steering, lane changing, and judgment are degraded and the driving performance of virtually all drivers is substantially impaired. During the debate on reauthorization of the federal surface transportation programs, an amendment that would require each state either to enact a 0.08 BAC law or face the loss of a portion of its Federal Highway Trust Fund monies passed the Senate and will likely be considered in the House. This proposal raises questions about the effectiveness and impacts of a 0.08 BAC law, the rights of states versus the federal government, and alternative ways to encourage the states to adopt stronger impaired driving countermeasures.
Colombia: The Problem of Illegal Narcotics and U.S. - Colombian Relations
The United States has long been concerned with Colombia as a major producer and trafficker of the illegal narcotics entering this country: first marijuana, then cocaine, and now also heroin. Colombia's drug trafficking business has been dominated by two cartels during the two decades in which cocaine trafficking became a major activity: first the Medellin cartel, which dominated during the 1980s and then the Cali cartel, which dominated during the early 1990s. With the arrests of the major Cali cartel leaders in the mid-1990s, independent traffickers have filled the void.
Veterans and Smoking-Related Illnesses: Congress Enacts Limits to Compensation
With enactment of P.L. 105-178 (H.R. 2400), the Transportation Equity Act for the 21 Century (TEA-21), Congress limited authority of the Department of Veterans st Affairs (VA) to grant service-connected compensation to veterans who, after the enactment date, claim that their smoking-related illnesses are traceable to tobacco use that began during their military service. P.L. 105-178's prohibition on most smokingrelated VA claims is the resolution of an issue with potentially explosive federal costs. Subsequent technical amendments included in P.L. 105-205, the Internal Revenue Service reform legislation, removed the implication that smoking may have been misconduct, and made other minor clarifications.
The Opioid Epidemic and the Food and Drug Administration: Legal Authorities and Recent Agency Action
This report focuses on the U.S. Food and Drug Administration (FDA) as a key player in federal efforts to curb the opioid epidemic. It provides an overview of FDA's role in approving new prescription drugs, including challenges of approval and regulation of opioid products; addresses FDA's multifaceted approach in responding, including recent agency action; and concludes with a discussion of selected opioid-related legislation in the 115th Congress.
Drug Certification of Mexico in 1999: Arguments For and Against Congressional Resolutions of Disapproval
This report presents arguments for and against congressional resolutions to disapprove President Clinton’s February 26, 1999 certification of Mexico as a fully cooperative country in efforts to control illicit narcotics.1 These resolutions (H.J.Res. 35--Bachus, and H.J.Res. 43--Mica and Gilman) would disapprove the President’s certification, but would permit him to avoid withholding of assistance to Mexico if he determined that vital national interests required such assistance.
Drug Certification Requirements and Congressional Modifications in 2001
This report provides a brief summary of the existing drug certification requirements for drug producing and drug-transit countries, background on the experience, criticisms, and reform efforts under these provisions; a summary of early congressional options and proposals advanced in 2001, with possible advantages and disadvantages; a summary of later initiatives with legislative activity; and (5) a tracking of legislative action on the major initiatives.
Drug Certification Requirements and Congressional Modifications in 2001-2002
This report provides a brief summary of the existing drug certification requirements for drug producing and drug-transit countries, background on the experience, criticisms, and reform efforts under these provisions; a summary of early congressional options and proposals advanced in 2001, with possible advantages and disadvantages; a summary of later initiatives with legislative activity; and (5) a tracking of legislative action on the major initiatives.
Drug Certification Requirements and Congressional Modifications in 2001-2002
This report provides a brief summary of the existing drug certification requirements for drug producing and drug-transit countries, background on the experience, criticisms, and reform efforts under these provisions; a summary of early congressional options and proposals advanced in 2001, with possible advantages and disadvantages; a summary of later initiatives with legislative activity; and (5) a tracking of legislative action on the major initiatives.
Drug Certification Requirements and Proposed Congressional Modifications in 2001
This report provides a brief summary of the existing drug certification requirements for drug producing and drug-transit countries, background on the experience, criticisms, and reform efforts under these provisions; a summary of early congressional options and proposals advanced in 2001, with possible advantages and disadvantages; a summary of later initiatives with legislative activity; and (5) a tracking of legislative action on the major initiatives.
Mexican Drug Certification Issues: U.S. Congressional Action, 1986-1998
No Description Available.
Mexican Drug Certification Issues: U.S. Congressional Action, 1986-2001
No Description Available.
Mexican Drug Certification Issues: U.S. Congressional Action, 1986-2002
No Description Available.
Mexico's Counter-Narcotics Efforts under Fox, December 2000 to April 2002
No Description Available.
Mexico's Counter-Narcotics Efforts under Fox, December 2000 to October 2004
No Description Available.
Mexico's Counter-Narcotics Efforts under Zedillo and Fox, December 1994-March 2001
No Description Available.
Mexico's Counter-Narcotics Efforts Under Zedillo, December 1994 to March 1998
No Description Available.
Mexico-U.S. Relations: Issues for Congress
This report explores the relationship between the United States and Mexico in terms of trade, drug trafficking, and cooperative disease control and management. Specifically, the report discusses the Mérida Initiative, the trade dispute involving the implementation of NAFTA trucking provisions, Secretary of State Clinton's March 2009 visit to Mexico, and the April 2009 outbreak of the H1N1 "swine flu" virus.
Smokeless Tobacco: Snuff and Chewing Tobacco; Bibliography-in-Brief, 1983-1987
No Description Available.
Smokeless Tobacco: Snuff and Chewing Tobacco; Bibliography-in-Brief, 1983-1987
No Description Available.
Haiti: Efforts to Restore President Aristide, 1991-1994
This report tracks the efforts to restore to office President Aristide of Haiti between the years 1991-1994. During this period, the main U.S. foreign policy concern was the restoration of the democratic process to Haiti. Closely related to this was the issue of Haitians attempting to flee to the United States by boat. Congressional concerns focused on human rights, Haitian migration, socioeconomic conditions, and drug trafficking.
Andean Counterdrug Initiative (ACI) and Related Funding Programs: FY2005 Assistance
This report discusses the funds and material support the U.S. has contributed to help Colombia and the Andean region fight drug trafficking since the development of Plan Colombia in 1999.
Andean Counterdrug Initiative (ACI) and Related Funding Programs: FY2006 Assistance
This report discusses the funds and material support the U.S. has contributed to help Colombia and the Andean region fight drug trafficking since the development of Plan Colombia in 1999.
Andean Counterdrug Initiative (ACI) and Related Funding Programs: FY2007 Assistance
This report discusses the funds and material support the U.S. has contributed to help Colombia and the Andean region fight drug trafficking since the development of Plan Colombia in 1999.
Colombia: Issues for Congress
Recent debate on U.S. policy toward Colombia has taken place in a context of concern for the volume of drugs readily available in the United States and elsewhere in the world, and regional security issues. The United States has made a significant commitment of funds and material support to help Colombia and the Andean region fight drug trafficking since the development of Plan Colombia in 1999. Congress passed legislation providing $1.3 billion in assistance for FY2000 (P.L. 106-246) and has provided more than $4 billion for programs in Colombia from FY2000 through FY2005 in both State Department and Defense Department counternarcotics accounts.
Drug Crop Eradication and Alternative Development in the Andes
The United States has supported drug crop eradication and alternative development programs in the Andes for decades. Colombia, Bolivia, and Peru collectively produce nearly the entire global supply of cocaine. In addition, Colombia has become a producer of high quality heroin, most of it destined for the United States and Europe. The United States provides counternarcotics assistance through the Andean Counterdrug Initiative (ACI). The program supports a number of missions, including interdiction of drug trafficking, illicit crop eradication, alternative development, and rule of law and democracy promotion. From FY2000 through FY2005, the United States has provided a total of about $4.3 billion in ACI funds.
ATPA Renewal: Background and Issues
This report outlines the various aspects of the Andean Trade Preference Act (ATPA), including significant dates and modifications. The ATPA extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. The purpose of ATPA is to promote economic growth in the Andean region and to encourage a shift away from dependence on illegal drugs by supporting legitimate economic activities.
ATPA Renewal: Background and Issues
The Andean Trade Preference Act (ATPA) extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. The purpose of ATPA is to promote economic growth in the Andean region and to encourage a shift away from dependence on illegal drugs by supporting legitimate economic activities. This report outlines the various aspects of the ATPA, including significant dates and modifications.
ATPA Renewal: Background and Issues
This report outlines the various aspects of the Andean Trade Preference Act (ATPA), including significant dates and modifications. The ATPA extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. The purpose of ATPA is to promote economic growth in the Andean region and to encourage a shift away from dependence on illegal drugs by supporting legitimate economic activities.
ATPA Renewal: Background and Issues
The Andean Trade Preference Act (ATPA) extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. The purpose of ATPA is to promote economic growth in the Andean region and to encourage a shift away from dependence on illegal drugs by supporting legitimate economic activities. This report outlines the impact and policy implications of the ATPA.
ATPA Renewal: Background and Issues
The Andean Trade Preference Act (ATPA) extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. The purpose of ATPA is to promote economic growth in the Andean region and to encourage a shift away from dependence on illegal drugs by supporting legitimate economic activities. This report outlines the various aspects of the ATPA, including significant dates and modifications.
ATPA Renewal: Background and Issues
The Andean Trade Preference Act (ATPA) extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. This report outlines the various aspects of the ATPA, including significant dates and modifications.
ATPA Renewal: Background and Issues
The Andean Trade Preference Act (ATPA) extends special duty treatment to certain U.S. imports from Bolivia, Colombia, Ecuador, and Peru that meet domestic content and other requirements. The purpose of ATPA is to promote economic growth in the Andean region and to encourage a shift away from dependence on illegal drugs by supporting legitimate economic activities. This report outlines the various aspects of the ATPA, including significant dates and modifications.
Transnational Organized Crime: Principal Threats and U.S. Responses
No Description Available.
Transnational Organized Crime: Principal Threats and U.S. Responses
No Description Available.
Hurricanes Katrina
The Department of Health and Human Services’ Substance Abuse & Mental Health Services Administration (SAMHSA) has three primary mechanisms of providing federal funding to meet the mental health and substance abuse prevention needs of victims of recent hurricanes: the Crisis Counseling Assistance and Training Program (CCP), SAMHSA Emergency Response Grants (SERG), and supplemental appropriations. CCPs may be of interest to Congress, as questions have arisen regarding their appropriate scope and duration following two previous large-scale emergency situations (the Oklahoma City bombing, and the September 11, 2001 terrorist attacks). SERG may also be of interest, as Congress may consider amending or suspending existing law to enhance the availability of grant money. Congress has already passed two supplemental appropriations . This may lead Congress to consider a range of oversight options. This report will be updated as needed.
Federal Assistance to States and Communities for the Control of Drug Abuse
This report discusses federal aid to states for use in preventing drug abuse.
U.S. Tobacco Production, Consumption, and Export Trends
No Description Available.
U.S. Tobacco Production, Consumption, and Export Trends
No Description Available.
International Convention Against Doping in Sport: Issues for Congress
The International Convention Against Doping in Sport seeks to harmonize anti-doping commitments for non-professional sports at the international level. Issues that may continue to arise as policymakers evaluate the Convention include its relationship to anti-doping regulations in professional sports and the legitimacy and effectiveness of current international anti-doping activities.
International Convention Against Doping in Sport: Issues for Congress
The International Convention Against Doping in Sport seeks to harmonize anti-doping commitments for non-professional sports at the international level. Issues that could arise as the Senate considers the Convention include its relationship to anti-doping regulations in professional sports, potential consequences that non-ratification could pose to the United States, and the legitimacy and effectiveness of current international anti-doping activities.
International Convention Against Doping in Sport: Issues for Congress
The International Convention Against Doping in Sport seeks to harmonize anti-doping commitments for non-professional sports at the international level. This Convention was adopted by the United Nations Educational, Scientific, and Cultural Organization (UNESCO) in 2005 and entered in force on February 1, 2007. Issues that could arise as the Senate considers the treaty include its relationship to anti-doping regulations in professional sports, potential consequences that non-ratification could pose to the United States, and the legitimacy and effectiveness of current international anti-doping activities.
International Drug Control Policy
This report discusses the scope of the international drug control problem, current measures in place. It includes sections that discuss: the global scope of the problem, strategic guidance, overall U.S. drug control funding, U.S. assistance for international counternarcotics programs, policy issues, and conclusions.
International Drug Control Policy
This report provides an overview of U.S. international drug control policy. It describes major international counternarcotics initiatives and evaluates the broad array of U.S. drug control policy tools currently in use. The report also considers alternative counterdrug policy approaches to current initiatives and raises several counterdrug policy issues and considerations for policy makers.
International Drug Control Policy
This report provides an overview of U.S. international drug control policy. It describes major international counternarcotics initiatives and evaluates the broad array of U.S. drug control policy tools currently in use. The report also considers alternative counterdrug policy approaches to international drug control initiatives and raises several counterdrug policy issues and considerations for policy makers.
International Drug Control Policy
This report provides an overview of U.S. international drug control policy. It describes major international counternarcotics initiatives and evaluates the broad array of U.S. drug control policy tools currently in use. The report also considers alternative counterdrug policy approaches to current initiatives and raises several counterdrug policy issues and considerations for policy makers.
International Drug Control Policy
This report provides an overview of U.S. international drug control policy. It describes major international counternarcotics initiatives and evaluates the broad array of U.S. drug control policy tools currently in use. The report also considers alternative counterdrug policy approaches to current initiatives and raises several counterdrug policy issues and considerations for policy makers.
International Drug Control Policy: Background and U.S. Responses
The report provides background information on drug cultivation, drug trafficking and the consequences of drug trade. This report discusses challenges created by the global illegal drug trade, including: undermining political and regional stability, bolstering the role and capabilities of transnational criminal organizations in the drug trade, and the burden caused by drug use an addition on local communities and economic development. In addition, this report discusses U.S. policy efforts to thwart illegal drug trade.
International Drug Control Policy: Background and U.S. Responses
This report discusses challenges created by the global illegal drug trade, including: undermining political and regional stability, bolstering the role and capabilities of transnational criminal organizations in the drug trade, and the burden caused by drug use an addition on local communities and economic development. In addition, this report discusses U.S. policy efforts to thwart illegal drug trade.
A Low Carbon Fuel Standard: State and Federal Legislation and Regulations
This report analyzes the draft California standards, and discusses how those standards might work. Next, the report analyzes federal Low Carbon Fuel Standard (LCFS) legislation proposed in the 110th Congress. Finally, the report analyzes what effects an LCFS might have on state and national fuel supplies.
Drug Offenses: Maximum Fines and Terms of Imprisonment for Violation of the Federal Controlled Substances Act and Related Laws
This is a chart of the maximum fines and terms of imprisonment that may be imposed as a consequence of conviction for violation of the federal Controlled Substances Act (CSA) and other drug supply and drug demand related laws. It lists the penalties for: heroin, cocaine, crack, PCP, LSD, marihuana (marijuana), amphetamine, methamphetamine, listed (precursor) chemicals, paraphernalia, date rape drugs, rave drugs, designer drugs, ecstasy, drug kingpins, as well as the other substances including narcotics and opiates assigned to Schedule I, Schedule II, Schedule III, Schedule IV, and Schedule V of the Controlled Substances Act and the Controlled Substances Import and Export Act (Title II and Title III of the Comprehensive Drug Abuse and Control Act).
Back to Top of Screen